CYPC19*17 POLYMORPHISM AS A RISK-FACTOR FOR NSAIDS-INDUCED ULCERS

  • Serhiy Tkach Ukrainian Scientifically Practical Center of Endocrine Surgery Ministry of Health of Ukraine, Ukraine
  • Lyudmyla Onischuk Bogomolets National Medical University, Ukraine
  • Alexandra Balabanseva S.I. Georgievsky Crimea State Medical University, Ukraine
Keywords: NSAID gastropathy, risk factors, CYP 2C19 polymorphism

Abstract

The new risk-factors for peptic ulcers induced by the use of nonsteroidal antiinflammatory drugs, such as polymorphism of different isoenzymes of cytochrome P450 were considered in the article. The aim of the research was to study different genetic polymorphism of several ferments CYP2C9 and CYP2C19 in inclination to NSAIDS-gastropathies by the way of estimation the risk of appearance of Helicobacter pylori (HP)-positive or Hp-negative NSAIDS- induced peptic ulcers, complicated or not with upper gastrointestinal bleeding.
124 persons were examined (76 men, 48 women in the age of 56,2+/–9,1 years) with Hp-positive or Hp-negative NSAIDS-induced peptic ulcers, that were performed genotyping of isoferments of cytochrome system (CYP2C9, CYP2C19). Based on investigations of 5 different isoenzymes (CYP 2C9*2, CYP 2C9*3, CYP 2C19*2, CYP 2C19*3 and CYP 2C19*17). It was founded that peptic ulcers are strictly associated only with CYP 2C19*17-genotype, possibly due to its involvement in arachidonic acid metabolism and gastroprotection. Thus, polymorphism CYP 2C19*17 can be considered as one of the risk factors for NSAID-gastropathy though the future researches are needed.

Downloads

Download data is not yet available.

Author Biography

Lyudmyla Onischuk, Bogomolets National Medical University

Department of internal medicine #1

References

Baldwin, R. M., Ohlsson, S., Pedersen, R. S., Mwinyi, J., Ingelman-Sundberg, M., Eliasson, E., Bertilsson, L. (2008). Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. British Journal of Clinical Pharmacology, 65 (5), 767–774.

doi: 10.1111/j.1365-2125.2008.03104.x

Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K. L., Furberg, C. D. et. al (2008). ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology, 103 (11), 2890–2907. doi: 10.1111/j.1572-0241.2008.02216.x

Blanco, G., Martínez, C., Ladero, J. M., Garcia-Martin, E., Taxonera, C., Gamito, F. G. et. al (2008). Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenetics and Genomics, 18 (1), 37–43. doi: 10.1097/fpc.0b013e3282f305a9

Carbonell, N., Verstuyft, C., Massard, J., Letierce, A., Cellier, C., Deforges, L. et. al (2010). CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin. Clinical Pharmacology & Therapeutics, 87 (6), 693–698. doi: 10.1038/clpt.2010.33

Chan, F. K. L. (2005). NSAID-Induced Peptic Ulcers and Helicobacter pylori Infection. Drug Safety, 28 (4), 287–300. doi: 10.2165/00002018-200528040-00002

Estany-Gestal, A., Salgado-Barreira, A., Sánchez-Diz, P., Figueiras, A. (2011). Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs. Pharmacogenetics and Genomics, 21 (7), 357–364. doi: 10.1097/fpc.0b013e328346d2bb

Goldstein, J. A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology, 52 (4), 349–355. doi: 10.1046/j.0306-5251.2001.01499.x

Harmsze, A. M., van Werkum, J. W., Hackeng, C. M., Ruven, H. J. T., Kelder, J. C., Bouman, H. J. et. al (2012). The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22 (3), 169–175. doi: 10.1097/fpc.0b013e32834ff6e3

Hunfeld, N. G., Mathot, R. A., Touw, D. J., van Schaik, R. H., Mulder, P. G., Franck, P. F. et. al. (2008). Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. British Journal of Clinical Pharmacology, 65 (5), 752–760. doi: 10.1111/j.1365-2125.2007.03094.x

Hunt, R. H., Lanas, A., Stichtenoth, D. O., Scarpignato, C. (2009). Myths and facts in the use of anti-inflammatory drugs. Annals of Medicine, 41 (6), 423–437. doi: 10.1080/07853890902887295

Ingelman-Sundberg, M., Sim, S. C., Gomez, A., Rodriguez-Antona, C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & Therapeutics, 116 (3), 496–526. doi: 10.1016/j.pharmthera.2007.09.004

Kaspera, R., Totah, R. A. (2009). Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opinion on Drug Metabolism & Toxicology, 5 (7), 757–771. doi: 10.1517/17425250902932923

Li-Wan-Po, A., Girard, T., Farndon, P., Cooley, C., Lithgow, J. (2010). Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. British Journal of Clinical Pharmacology, 69 (3), 222–230. doi: 10.1111/j.1365-2125.2009.03578.x

Ma, J., Yang, X. Y., Qiao, L., Liang, L. Q., & Chen, M. H. (2008). CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy. Journal of Digestive Diseases, 9 (2), 79–83. doi: 10.1111/j.1751-2980.2008.00326.x

Malfertheiner, P., Megraud, F., O’Morain, C. A., Atherton, J., Axon, A. T. R., Bazzoli, F. et. al (2012). Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut, 61 (5), 646–664. doi: 10.1136/gutjnl-2012-302084

McNamara, D. (2004). Gastro-oesophageal reflux disease and ulcer disease in Europe: NSAID-related gastroduodenal pathology. The Burden of Gastrointestinal Diseases in Europe, 31–36.

Micklewright, R., Lane, S., Linley, W., McQuade, C., Thompson, F., Maskrey, N. (2003). NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors*. Alimentary Pharmacology and Therapeutics, 17 (3), 321–332. doi: 10.1046/j.1365-2036.2003.01454.x

Musumba, C. O., Jorgensen, A., Sutton, L., Van Eker, D., Zhang, E., O’Hara, N. et. al (2012). CYP2C19*17 Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease. Clinical Pharmacology & Therapeutics, 93 (2), 195–203. doi: 10.1038/clpt.2012.215

Musumba, C., Pritchard, D. M., Pirmohamed, M. (2009). Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Alimentary Pharmacology & Therapeutics, 30 (6), 517–531. doi: 10.1111/j.1365-2036.2009.04086.x

Musumba, C., Jorgensen, A., Sutton, L., Eker, D., Moorcroft, J., Hopkins, M. et. al (2012). The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Alimentary Pharmacology & Therapeutics, 36 (1), 48–56. doi: 10.1111/j.1365-2036.2012.05118.x

Pedersen, R. S., Brasch-Andersen, C., Sim, S. C., Bergmann, T. K., Halling, J., Petersen, M. S. et. al (2010). Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. European Journal of Clinical Pharmacology, 66 (12), 1199–1205. doi: 10.1007/s00228-010-0864-8

Pilotto, A., Seripa, D., Franceschi, M., Scarcelli, C., Colaizzo, D., Grandone, E. et. al (2007). Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms. Gastroenterology, 133 (2), 465–471. doi: 10.1053/j.gastro.2007.05.025

Rosemary, J., Adithan, C. (2007). The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance. Current Clinical Pharmacology, 2 (1), 93–109. doi: 10.2174/157488407779422302

Scarpignato, C., Hunt, R. H. (2010). Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention. Gastroenterology Clinics of North America, 39 (3), 433–464. doi: 10.1016/j.gtc.2010.08.010

Scott, S. A., Martis, S., Peter, I., Kasai, Y., Kornreich, R., Desnick, R. J. (2011). Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. The Pharmacogenomics Journal, 12 (4), 297–305. doi: 10.1038/tpj.2011.5

Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., Klein, T. E. (2012). PharmGKB summary. Pharmacogenetics and Genomics, 22 (2), 159–165. doi: 10.1097/fpc.0b013e32834d4962

Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A. et. al (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics, 90 (2), 328–332. doi: 10.1038/clpt.2011.132

Shiotani, A., Sakakibara, T., Yamanaka, Y., Nishi, R., Imamura, H., Fujita, M. et. al (2009). The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. Journal of Gastroenterology, 44 (7), 717–725. doi: 10.1007/s00535-009-0068-0

Sibbing, D., Gebhard, D., Koch, W., Braun, S., Stegherr, J., Morath, T. (2010). Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of Thrombosis and Haemostasis, 8 (8), 1685–1693. doi: 10.1111/j.1538-7836.2010.03921.x

Vergara, M., Catalan, M., Gisbert, J. P., Calvet, X. (2005). Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Alimentary Pharmacology and Therapeutics, 21 (12), 1411–1418. doi: 10.1111/j.1365-2036.2005.02444.x

Yasar, U., Lundgren, S., Eliasson, E., Bennet, A., Wiman, B., de Faire, U., Rane, A. (2002). Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochemical and Biophysical Research Communications, 299 (1), 25–28. doi: 10.1016/s0006-291x(02)02592-5

Zabalza, M., Subirana, I., Sala, J., Lluis-Ganella, C., Lucas, G., Tomas, M. et. al (2011). Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart, 98 (2), 100–108. doi: 10.1136/hrt.2011.227652


👁 567
⬇ 325
Published
2016-06-10
How to Cite
Tkach, S., Onischuk, L., & Balabanseva, A. (2016). CYPC19*17 POLYMORPHISM AS A RISK-FACTOR FOR NSAIDS-INDUCED ULCERS. EUREKA: Health Sciences, (3), 24-30. https://doi.org/10.21303/2504-5679.2016.00096
Section
Medicine and Dentistry